L García-García

Laboratorio de investigación en Oncohematología, Fundación de Investigación Biomédica, Hospital Infantil Universitario Niño Jesús, Madrid, 28009, Spain

Use of anti-GD2 (Dinutuximab) as a target for CAR-T cells immunotherapy in Neuroblastoma

B Díez

Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain

Transposon-based CAR-T cells for lymphoma treatment

M Cortijo-Gutiérrez

GENyO

Creation of next generation CAR-T by Repurposing endogenous immune pathways

A López

CIEMAT/CIBERER

Generation of CAR-T cells for the treatment of squamous cell carcinomas in Fanconi anemia patients

P Justicia-Lirio

GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia; LentiStem Biotech

Development of 4th generation regulated CAR-T cells (iTRUCKs) targeting pancreatic solid tumors

K Pavlovic

GENyO- Centro de Genomica e Investigacion Oncologica: Pfizer / Universidad de Granada / Junta de Andalucia; Instituto Maimónides de Investigación Biomédica de Córdoba

TCR/HLA-I double knockout CAR-T cells maintain lytic ability with reduced allogenicity

P Garcia-Rodriguez

Instituto de Salud Carlos III

Challenges of CAR-T cells in solid tumours: modelling immunotherapy with 3D osteosarcoma cultures

P Barbao

IDIBAPS

Chronic antigen exposure induces CAR-T cell loss of function and a dysregulated gene expression profile leading to treatment failure in solid tumors

I Andreu-Saumell 

IDIBAPS

Elucidating the role of PD-1 genome editing in CAR-T cell function

P Rodríguez-Márquez 

Hemato-Oncology Program. CIMA Universidad de Navarra. IdiSNA. Pamplona, 31008. Spain

CAR density influences CAR-T antitumoral efficacy and correlates with clinical outcome

P Heredia 

Genomic Medicine Department, GENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Av. de la Illustration 114, Granada, 18016, Spain.

Development and validation of a scalable method for the production of “off-the-shelf” exosomes-based products derived from CAR-T cells

J Peña Martín 

Universidad de Granada

Exogenous miRNAs as theraputic agents against malignant melanoma